Clinical Trial Update: A Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant trial evaluating TQB2102 for HER2-positive breast cancer is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• TQB2102

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: Breast Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING